Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integrated BioPharma ( (INBP) ) has shared an update.
On April 14, 2026, Integrated BioPharma, Inc. and its wholly owned subsidiary Manhattan Drug Company, Inc. received notice from PNC Bank that the expiration date of their existing line of credit, originally set for April 15, 2026 under a 2025 promissory note, was extended to July 14, 2026. The extension, effective April 16, 2026 and subject to PNC’s discretion to prolong it further, gives the companies additional short-term financing flexibility and helps mitigate near-term refinancing risk for stakeholders.
The revised maturity date of the credit facility temporarily eases pressure on Integrated BioPharma’s liquidity position and supports continuity in its working capital management. By securing extra time before the facility expires, the company and its subsidiary gain a window to maintain operations, negotiate future financing, or adjust capital structure without an immediate credit deadline.
Spark’s Take on INBP Stock
According to Spark, TipRanks’ AI Analyst, INBP is a Neutral.
The score is held back primarily by weakening operating fundamentals (sharp TTM revenue decline, low gross margin, and a move back to net losses). Offsetting this are a low-risk balance sheet with minimal leverage and currently positive free cash flow. Technical indicators are mildly bearish/neutral and valuation is moderate, resulting in an overall mid-range score.
To see Spark’s full report on INBP stock, click here.
More about Integrated BioPharma
Integrated BioPharma, Inc. is a life sciences company operating through subsidiaries such as Manhattan Drug Company, Inc., with activities that include pharmaceutical or nutraceutical-related services and products. The firm relies on commercial banking relationships, including revolving credit facilities, to support its ongoing operations and liquidity needs.
Average Trading Volume: 10,721
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.72M
See more insights into INBP stock on TipRanks’ Stock Analysis page.